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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.04.014Objective: Endothelial injury during the harvest of saphenous vein grafts might play
an important role in the development of vein graft disease after coronary artery
bypass grafting. Using a murine autologous arterialized vein patch model, we tested
whether the initial ischemic insult of vein grafts was linked to the later development
of graft neointimal hyperplasia and whether the restoration of the cyclic adenosine
monophosphate second messenger pathway would attenuate the development of
neointimal hyperplasia.
Methods: A segment of the external jugular vein of a mouse was grafted onto its
abdominal aorta. Three weeks after the operation, the degree of neointimal hyper-
plasia of the implanted graft was compared among (1) grafts without preservation,
(2) grafts with 2 hours of preservation (25°C) in heparinized saline, and (3) grafts
with 2 hours of preservation in heparinized saline in the presence of a cyclic adenosine
monophosphate analog. In addition, cyclic adenosine monophosphate contents of vein
grafts and leukocyte adherence to the graft endothelium were assessed.
Results: Cyclic adenosine monophosphate contents were significantly decreased
after 2 hours of preservation (212  8 vs 156  5 pmol/L, P  .01). The grafts
preserved for 2 hours showed greater neointimal hyperplasia compared with the grafts
without preservation (neointimal expansion, 68.7%  9.6% vs 46.1%  4.8%; P 
.01). The addition of a cyclic adenosine monophosphate analog to the preservation
solution significantly suppressed neointimal hyperplasia of grafts preserved for 2 hours
(44.3%  5.0%). Inhibiting the cyclic adenosine monophosphate–dependent protein
kinase by adding Rp-cAMPS abrogated the beneficial effects. Furthermore, grafts
preserved for 2 hours had significantly more leukocytes adhering to the graft endothe-
lium 24 hours after the operation compared with nonpreserved grafts, which was
significantly reduced by the cyclic adenosine monophosphate treatment.
Conclusions: Ischemic insult during vein graft harvest and preservation is a key
factor in the development of vein graft neointimal hyperplasia at least in part caused
by the depletion of cyclic adenosine monophosphate. We conclude that stimulation
of the cyclic adenosine monophosphate second messenger pathway might be a
potential strategy for the prevention of vein graft disease.
Coronary artery bypass grafting is widely accepted for myocardialrevascularization of patients with ischemic heart disease. In thissetting the saphenous vein remains the most commonly used con-duit, despite the increasing use of arterial grafts. However, the rateof saphenous vein graft failure remains high. Vein graft failure iscomprised of 3 discrete processes: thrombosis, neointimal hyper-
plasia, and atherosclerosis.1-3 Various clinical strategies aimed at the prevention of
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anticoagulant drugs, risk factor modification, and lipid-
lowering drugs. However, most of these clinical trials have
not addressed the problem of neointimal hyperplasia be-
cause the pathogenesis of this lesion is complex and remains
obscure.
Endothelial dysfunction is thought to be an initial step in
the development of neointimal hyperplasia.4 Mechanical or
ischemic insults might enhance gene expression of adhesion
molecules, growth factors, cytokines, and matrix proteins in
endothelial cells, followed by smooth muscle cell migra-
tion-proliferation and accumulation of extracellular ma-
trix.1,2,5-8 Therefore maintenance of vascular integrity and
function during the early period of vein graft implantation is
one of the key factors linked to the subsequent development
of neointimal hyperplasia. An important intracellular sec-
ond messenger associated with endothelial cell regulation of
vascular homeostatic properties is cyclic adenosine mono-
phosphate (cAMP).9-12 Ischemia-driven cAMP deficiency
in preserved organs is a critical mechanism by which vas-
cular homeostasis might be disrupted.9,11-14 This study was
designed to test the hypothesis that initial ischemic insult
during harvest and storage of vein grafts is a central factor
in the development of neointimal hyperplasia and that en-
hancement of graft preservation through supplementation of
the cAMP pathway might attenuate vein graft neointimal
hyperplasia.
Methods
Mice and Vein Graft Procedure
Male C57BL/6J mice were purchased from Jackson Laboratories.
All procedures were approved by the Institutional Animal Care
and Use Committee at Columbia University. The investigation
conforms to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (National Insti-
tutes of Health publication no. 85-23, revised 1996). The surgical
procedures used were modified from those described by Shi and
associates.15 Mice (12-16 weeks of age) were anesthetized by
means of intraperitoneal injection of ketamine (50 mg/kg) and
xylazine (5 mg/kg). A midline skin incision was made on the neck,
and the right external jugular vein was dissected. A segment of the
jugular vein (5 mm long) was transected after ligation at both ends
with 8-0 sutures. This segment was opened longitudinally, washed
with saline solution containing 100 U/mL heparin, and stored at
25°C for up to 2 hours in heparinized saline. After closing the neck
incision with a 6-0 nylon suture, a midline skin incision was made
on the abdomen. The abdominal aorta and the inferior vena cava
were exposed. The segment of the abdominal aorta between the
renal arteries and the aortic bifurcation was temporally occluded
with a microvascular clamp (Roboz Surgical Instrument Co), and
a longitudinal incision (of about the same length as the vein patch)
was made. The defect of the aorta was repaired by suturing the
prepared vein patch into the defect of the aorta with an 11-0
continuous suture around the margin of the patch. Contact between
the instruments and the vein graft endothelium was avoided as
much as possible throughout the procedure. After the vascular
130 The Journal of Thoracic and Cardiovascular Surgery ● Januclamp was removed, the vein patch was inspected for adequacy of
repair. The operation was considered successful if strong pulsation
was confirmed in both the graft and native aorta without significant
bleeding. If there were no pulsations or pulsations were diminished
within a few minutes of restoration of blood flow, the procedure
was considered a surgical failure. Cefazolin (50 mg/kg) was ad-
ministered, and the skin incision was closed with a 6-0 nylon
suture. Buprenorphine (2.5 mg/kg) was administered subcutane-
ously for postoperative analgesia. The duration of the entire pro-
cedure was approximately 50 minutes.
Figure 1 demonstrates the surgical procedure. The success rate
of the operation exceeded 95%. A total of 107 mice were included
in this study. Ninety-three animals survived until their designated
time of harvest. Two mice died intraoperatively from complica-
tions caused by anesthesia, and 12 mice died postoperatively as a
result of ileus (n  3), intra-abdominal bleeding (n  2), graft
occlusion (n  2), or unknown cause (n  5). The overall success
rate was 87%.
Graft Preservation
The base preservation solution consisted of saline with heparin
(100 U/mL) alone or with the following additional reagents: N6,2'-
O-dibutyryl adenosine 3':5'-cyclic monophosphate (db-cAMP; 2
mmol/L); 8-bromoadenosine-cAMP (8-Br-cAMP; 0.1 mmol/L);
and 8-Br-cAMP (0.1 mmol/L) plus Rp-cAMPS (0.25 mmol/L), the
Rp isomer of adenosine 3',5'-monophosphate (Sigma).16 The con-
centrations of these cAMP analogues have been shown to be the
optimal dose on the basis of previous studies,12,13,16 and adding
cAMP analogues did not change the acidity of the base preserva-
tion solution.
Morphology
Mice were killed at various time points after surgical intervention
and perfusion fixed with 10% formaldehyde at physiologic pres-
sure. The grafts, together with a short segment of the native
abdominal artery, were harvested and cut at the center. The spec-
imens were embedded in medium (OCT compound) and frozen at
80°C. The section (5 m) at the midportion of each composite
graft was stained with hematoxylin and eosin or elastic van Gieson
stain (Sigma), and the degree of neointimal expansion was ana-
lyzed quantitatively with a Zeiss microscope and image analysis
system (Media Cybernetics). The consistency of the neointimal
formation in the central portion of the graft was histologically
confirmed by analyzing serial sections from the center to the
proximal and distal ends of the graft (data not shown).15 The
neointima of the vein graft was defined as the region between the
lumen and the adventitia. Neointimal cell number was calculated
by counting the number of nuclei visible in sections stained with
hematoxylin and eosin. The percentage of neointimal expansion
was calculated as follows: 100  (Neointimal area/Neointimal
area  Luminal area). These quantifications were performed by
an observer blinded to the experimental circumstances. Masson
trichrome staining was performed according to the manufacturer’s
instruction (Sigma).
cAMP Assay
Segments of inferior vena cava were taken without (n 4) or with
2 hours of preservation in the heparinized saline solution (25°C, n
ary 2005
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samples were ground to a fine powder under liquid nitrogen,
weighed, and homogenized in 10 volumes of 0.1 N HCl. cAMP
immunoassay was performed according to the manufacturer’s in-
struction (R&D Systems Inc).
En Face Immunofluorescence
The procedure used in this study was similar to that reported by
Zou and colleagues17 and Dietrich and coworkers.18 Vein patch
was retrieved 24 hours after the operation, mounted on a glass slide
with the endothelium side up, and air-dried for 1 hour at room
temperature. The segments were fixed in cold acetone (20°C) for
10 minutes and rinsed in phosphate-buffered saline. The segments
were then incubated with rat monoclonal antibody to macro-
phage-1 antigen (MAC-1, CD116/CD18) (1:25, Pharmingen) for
30 minutes and visualized with fluorescein isothiocyanate–labeled
rabbit anti-rat IgG (1:25, Sigma). MAC-1–positive cells were
blindly counted at 400 magnification in 10 fields of each seg-
ment.
Immunohistochemistry
Representative sections (5 m) were immunostained with rat
anti-platelet endothelial cell adhesion molecule-1 (anti-PECAM-1,
anti-CD31) antibody (1:100, Pharmingen), rat anti-MAC-1 anti-
body (1:50, Pharmingen), and hamster anti–intercellular adhesion
molecule 1 (anti-ICAM-1) antibody (1:100, Pharmingen). Sections
were blocked with hydrogen peroxide (0.3%) in methanol for 10
minutes. Blocking was performed with goat serum (4%) and
Figure 1. Photograph (a) and schematic representat
implantation model. A 5-mm-long vein segment taken
abdominal aorta after preservation. IVC, Inferior venabovine serum albumin (1%) in phosphate-buffered saline. Primary
The Journal of Thoraciantibodies were added to slides and incubated overnight at 4°C.
Secondary antibodies (1:100; anti-hamster or anti-rat IgG, Pharm-
ingen) were added for 30 minutes at room temperature. Sections
were reacted with horseradish peroxidase–conjugated streptavidin
(1:100, Sigma) for 30 minutes at room temperature and developed
with 3.3'-diaminobenzidine (DAB substrate kit, Vector).
Statistical Analysis
All data are expressed as means  SEM. The Student unpaired t
test for a comparison between 2 groups or analysis of variance
with post hoc analysis using the Bonferroni-Dunn test for a com-
parison among more than 2 groups was used to determine signif-
icant difference. All analyses were performed by using the Stat-
view statistical package, version J5.0 (Abacus Concepts Inc).
Results
Neointimal Formation in Jugular Vein Autograft
Figure 2 shows the representative histologic sections of vein
patch grafts that had been implanted onto the abdominal
aorta immediately after harvest without preservation. Elas-
tic van Gieson stain (Figure 2, a) showed that neointimal
hyperplasia developed in the vein patch graft 21 days after
the operation. The neointima formed primarily in associa-
tion with the venous part of the composite vessel (black
arrows) and not the arterial part, which is easily distin-
guished from the venous part by the existence of the elastic
b) demonstrating the procedures of the vein patch
the right external jugular vein was sutured onto the
; Ao, aorta.ion (
fromlaminas (stained as black). Masson trichrome stain (Figure
c and Cardiovascular Surgery ● Volume 129, Number 1 131
Surgery for Acquired Cardiovascular Disease Sakaguchi et al
A
CD2, b) indicated that the bulk of the lesion was formed by
collagen (blue) and smooth muscle cells (red), which were
visible by means of -actin staining (not shown). PECAM-1
(CD31) staining indicates some varieties of continuity of the
endothelium in the venous part at day 1 (Figure 2, c), which
Figure 2. Photomicrographs of cross-sections of jugu
oriented with the vein patch on top and the artery seg
21-day samples shows elastic lamina of the arterial w
White arrows indicate sutures approximately correspo
arterial wall. Masson trichrome stain for postoperative
the cellular portion as red (b). Immunohistologic stain
for postoperative days 1 (c, f, and i), 7 (d, g, and j), and
[a and b] or 400 (c-k).became more continuous at days 7 and 21 (Figure 2, d and
132 The Journal of Thoracic and Cardiovascular Surgery ● Janue). MAC-1 (CD11b/18) monocytes-macrophages were de-
tected at the luminal surface at 1 day after the operation and
were seen transmurally by 3 weeks (Figure 2, f-h). MAC-1
cells were predominant in the neointima of the vein graft at
postoperative day 7 and decreased their fraction in the
in–abdominal aorta composite vessels. Sections are
on bottom. Elastic van Gieson stain for postoperative
as black, muscle as yellow, and collagen as red (a).
g to the junction of the vein patch (black arrows) and
ay samples shows the extracellular matrix as blue and
r PECAM-1 (CD31; c-e), MAC-1 (f-h), and ICAM-1 (i-k)
, h, and k) is also shown. (Original magnification 100lar ve
ment
all
ndin
21-d
ing fo
21 (eneointima at postoperative day 21, when they were replaced
ary 2005
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receptor for MAC-1, in the vein graft significantly increased
1 day after implantation and continued to be increased at
postoperative days 7 and 21 (Figure 2, i-k).
Accelerated Neointimal Formation in Jugular Vein
Autograft by Ischemic Preservation
Figure 3 shows elastic van Gieson–stained micrographs of a
section of the jugular vein–abdominal aorta composite ves-
sels 21 days after the operation (Figure 3, a and b) and
statistical data in terms of neointimal cell number (Figure 3,
d), neointimal area (Figure 3, e), and percentage of neoin-
timal expansion (Figure 3, f), which was calculated as
described (Figure 3, c). Even without preservation, im-
planted vein grafts showed neointimal formation 3 weeks
after the operation. When vein grafts were subjected to 2
Figure 3. a and b, Influence of perioperative ischemic i
grafts. Elastic van Gieson–stained sections of jugular
operation are shown: a, vein graft that had been imp
preservation period; b, vein graft subjected to 2 hours
(Original magnification 100.) c, Schematic representa
data of the total neointimal cell number (d), neointim
postoperative day 21 are shown as means  SEM for
nonpreservation group, 5 in the 1-hour preservation gr
< .01.hours of preservation, they exhibited a significant increase
The Journal of Thoraciin the severity of neointimal hyperplasia in terms of neoin-
timal cell number (Figure 3, d; 454  77 in nonpreserved
grafts vs 1081  173 cells/neointimal area in 2-hour pre-
served grafts; P  .01), neointimal area (Figure 3, e; 1.759
 0.584 vs 5.269  0.820  105 m2, respectively; P 
.05), and neointimal expansion (46.1% 4.8% vs 68.7% 
9.6%, respectively; P  .01).
cAMP contents
Compared with no preservation, 2 hours of preservation was
associated with significantly decreased cAMP content (212
 8 vs 156 5 pmol/L, respectively; P .01; Figure 4, a).
Reduced Neointimal Formation by cAMP Treatment
Figure 4, b shows the effects of cAMP treatment during 2
hours of preservation on the development of neointimal
on the development of neointimal hyperplasia of vein
abdominal aorta composite vessels 21 days after the
ed immediately after harvest, without an intervening
reservation in heparinized saline before implantation.
of a cross-section of the composite vessel. Statistical
ea (e), and percentage of neointimal expansion (f) at
group. Numbers of grafts were as follows: 15 in the
and 9 in the 2-hour preservation group. *P < .05, **Pnjury
vein–
lant
of p
tion
al ar
each
oup,expansion of vein grafts 21 days after the operation. Adding
c and Cardiovascular Surgery ● Volume 129, Number 1 133
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mmol/L) to the preservation solution resulted in markedly
diminished neointimal formation at 3 weeks (neointimal
expansion is 68.7%  9.6% without additives [A] vs
51.0%  4.7% with db-cAMP [B], P  .05). To demon-
strate that the beneficial effects of db-cAMP were not spe-
cific for this cAMP analog and accrue through activation by
cAMP of the cAMP-dependent protein kinase, an additional
series of experiments was performed. Incorporation of the
membrane-permeable cAMP analog 8-Br-cAMP (0.1
mmol/L) into the preservation solution caused a similar
Figure 4. a, cAMP contents in the harvested vein graft. b, Effect
of cAMP analogues (db-cAMP and 8-Br-cAMP) on neointimal
expansion of vein grafts. The vein patch was stored in heparin-
ized saline without any additives (A); with cAMP analog db-
cAMP (2 mmol/L; B), 8-Br-cAMP (0.1 mmol/L; C), or 8-Br-cAMP (0.1
mmol/L); and with the cAMP-dependent protein kinase inhibitor
Rp-cAMPS (0.25 mmol/L; D). After 2 hours of preservation, the vein
patch was implanted onto the abdominal aorta of the same mouse
and harvested at postoperative day 21. Data are shown as means
 SEM for each group. Numbers of grafts were as follows: A, 9;
B, 9; C, 9; D, 8. *P < .05, **P < .01.reduction of neointimal formation at 3 weeks (44.3% 
134 The Journal of Thoracic and Cardiovascular Surgery ● Janu5.0% [C] vs without additives [A], P .01). When the same
dose of 8-Br-cAMP was added to the preservation solution
in the presence of additional cAMP-dependent protein ki-
nase inhibitor, Rp-cAMPS (0.25 mmol/L), the beneficial
effects of the cAMP analog with respect to diminishing
neointimal formation were abolished (62.1% 6.2% [D] vs
with 8-Br-cAMP only [C], P  .01).
Leukocyte Adhesion-Infiltration to Vein Grafts
Cells adhering to the endothelial surface were visualized
with a rat monoclonal antibody recognizing MAC-1 leu-
kocytes (CD11b/CD18; Figure 5, a-c). Significant numbers
of MAC-1 leukocytes (ie, monocytes-macrophages) were
observed adherent to the surface of nonpreserved vein graft
segments a day after the operation (Figure 5, a). The num-
ber of MAC-1 leukocytes was significantly greater in
grafts exposed to 2 hours of preservation than in nonpre-
served vein grafts (P .05; Figure 5, b and d). Furthermore,
adding db-cAMP to the preservation solution resulted in
markedly decreased MAC-1 cells in the vein grafts pre-
served for 2 hours (P  .05; Figure 5, c and d). Immuno-
staining for MAC-1 in the grafts harvested on day 21
showed that more MAC-1 cells were detected in the neo-
intima of 2-hour preserved grafts (Figure 5, f) compared
with those in nonpreserved grafts (Figure 5, e) and 2-hour
preserved grafts treated with cAMP (Figure 5, g). These
results indicate that leukocyte adhesion to the endothelium
is one of the earliest cellular events in vein graft disease, and
the beneficial effect of cAMP on preventing vein graft
disease was partly due to inhibition of leukocyte adhesion.
Discussion
Early endothelial cell injury has been focused on as a key
factor contributing to the later development of vein graft
failure.4,19-21 Damage to endothelial cells is caused by sev-
eral factors, including mechanical manipulation during har-
vest,6,19 ischemia during graft preservation,5,10,22 and in-
creased shear stress caused by higher arterial blood pressure
once implanted.8,23-25 These factors might stimulate endo-
thelial cells to release inflammatory mediators and growth
factors with suppression of the anticoagulant cofactors, re-
sulting in the later development of intimal hyperplasia.1,3,4
In this study we focused on ischemia-induced endothelial
dysfunction. Previous histochemical analyses have sug-
gested that structural derangements in the harvested veins
can be detected within 2 hours of storage.4,22 The level of
active extracellular signal–regulated kinase in human saphe-
nous vein is markedly increased after 50 minutes of incu-
bation in normal saline solution.7 Recently, Tatte and asso-
ciates22 assessed the structural and functional integrity of
human saphenous vein segments stored in multiple preser-
vation solutions using multiphoton microscopy. They
showed that within 60 minutes of harvest and storage in
ary 2005
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blood, calcium mobilization and nitric oxide generation
were markedly diminished, with more than 90% of endo-
thelial cells no longer viable in the vein. In this study vein
grafts preserved in heparinized saline for 2 hours showed
significantly decreased tissue cAMP contents and signifi-
cantly increased leukocyte adherence, followed by a marked
increase in neointimal expansion 21 days after the operation
compared with that seen in nonpreserved grafts. These
results indicate that early endothelial damage caused by
ischemic preservation might be an important contributor to
the later vein graft remodeling.
cAMP is known to be an important intracellular second
messenger associated with endothelial cell regulation of
vascular homeostatic properties. Previous studies have
Figure 5. Leukocyte adhesion-infiltration to the vein p
cells adhering to the endothelium of the vein patch (a-c
to 2 hours of preservation before implantation without
hours of preservation with added cAMP analog db-cAM
to the surface of the vein patch. Data are shown as me
staining demonstrates the presence of MAC-1 cell infi
magnification 400.)shown that stimulation of the cAMP pathway prevents
The Journal of Thoracineointimal formation after balloon injury of the rat carotid
artery and proliferation of vascular smooth muscle cells in
vitro.26-28 cAMP also inhibits tumor necrosis factor –in-
duced release of IL-6 and migration of vascular smooth
muscle cells cultured from human saphenous vein.14 In
porcine saphenous vein and carotid artery interposition
grafts, cAMP-synthesizing capacity is significantly down-
regulated at 1 month after implantation, which might be
relevant to the pathophysiology of early vein graft fail-
ure.29,30 A recent report of the 5-year interim results of a
randomized clinical trial of graft patency after coronary
artery bypass surgery showed high patency of saphenous
vein grafts (94%), speculating that bathing vein grafts in
phosphodiesterase III inhibitor before implantation is one of
the causes associated with the very low rate of graft fail-
. En face immunofluorescence demonstrated MAC-1
ein graft without preservation; b, vein grafts subjected
rvation solution additive; c, vein grafts subjected to 2
riginal magnification 200.) d, MAC-1 cells adhered
SEM for each group (n  10). Immunohistochemical
on in vein grafts at postoperative day 21 (e-g). (Originalatch
): A, v
prese
P. (O
ans 
ltratiure.31 Furthermore, we have previously reported that in
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way at the time of preservation not only improved acute
allograft function but also reduced the severity of trans-
plant-associated coronary artery disease in grafts examined
2 months after surgical intervention.16 The donor hearts
preserved for 120 minutes in the presence of db-cAMP
showed significantly more nitric oxide production and less
superoxide release, followed by less neointimal hyperplasia
60 days after transplantation, compared with that seen in the
control hearts preserved without the cAMP analog. In this
study, on the basis of the finding that tissue cAMP contents
were significantly decreased after 2 hours of preservation,
we hypothesized that the restoration of the cAMP pathway
would enhance vein graft preservation and thus attenuation
of the later development of neointimal hyperplasia.
cAMP regulates induction of a distinct set of genes,
including TNFA, IL6,14 TF, the gene encoding E-selectin,
VCAM1,32,33 and ICAM1.34 Adhesion molecules play an
important role in leukocyte adhesion to the endothelium,
which is a primary step in the early stage of atherosclero-
sis.35 Several lines of evidence have suggested that ICAM-
1/MAC-1–dependent cellular interaction is involved in a
number of inflammatory processes and in atherosclerosis
through mononuclear cell adhesion and migration.17,18,36,37
Zou and associates17 have shown that neointimal hyperpla-
sia of vein bypass grafts was significantly reduced in
ICAM-1–deficient mice compared with in wild-type ani-
mals. This is consistent with our preliminary study (data not
shown). In this study MAC-1 cells adhering to the vein
graft surface were significantly increased by 2 hours of
preservation, and cAMP treatment markedly suppressed
leukocyte adherence. In addition, ICAM-1 expression of the
graft surface was increased by ischemic preservation (data
not shown). Therefore inhibition of leukocyte adhesion by
reduction of ICAM-1 expression might be one of the im-
portant underlying mechanisms by which cAMP treatment
suppressed neointimal expansion of vein grafts.
Several animal models have been developed to clarify
the underlying mechanism of vein graft remodeling. Murine
genetic models have considerable advantages over other
animal systems in that they overcome the need to administer
factors or their inhibitors. Zou and associates17,38,39 estab-
lished the first murine model of vein graft arteriosclerosis
wherein the external jugular vein or inferior vena cava were
autografted-isografted into carotid arteries by using the cuff
technique. Shi and coworkers15 also reported another mu-
rine model in which a patch cut from the external jugular
vein was grafted to repair a surgically created defect in the
carotid artery. In the current study we used a murine vein
patch implantation model with some modification of that
reported by the latter. The vein patch taken from the exter-
nal jugular vein was implanted onto the abdominal aorta of
the same animal. This method is technically easier than that
136 The Journal of Thoracic and Cardiovascular Surgery ● Januof Shi and coworkers15 and provides a means to avoid
technical problems of interposition caused by size mismatch
of the vein and artery. We believe that this model represents
a significant advance toward understanding the pathogene-
sis and treatment of vein graft disease.
In summary, our data indicate that initial ischemic insult
plays an important role in the later development of vein
graft neointimal hyperplasia and that stimulation of the
cAMP second messenger pathway at the time of graft har-
vest might be a potential strategy for the prevention of vein
graft disease.
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